Buys
Open market- Shares
- Avg price
- Total value
Third Rock Ventures V, L.P. - 10%+ Owner at Rapport Therapeutics, Inc.
Issuer-level insider activity
- Role
- 10%+ Owner
- Issuer ticker
- RAPP on Nasdaq
- Entity type
- Company
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
Past-year transaction volume for Third Rock Ventures V, L.P. in Rapport Therapeutics, Inc.
Sells
Open market- Shares
- -854,708
- Avg price
- $40.24
- Total value
- -$34,391,226
Net
Past year- Shares
- -854,708
- Share %
- -100%
- Total value
- -$34,391,226
Reported holdings for Third Rock Ventures V, L.P. in Rapport Therapeutics, Inc.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 6,280,525
- Estimated value
- $251,516,184
- Report date
- 26 May 2026
- Price
- $40.05
- Ownership
- Direct
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 6,280,525
- Estimated value
- $251,516,184
- Report date
- 26 May 2026
- Price
- $40.05
- Ownership
- Direct
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 6,280,525
- Estimated value
- $251,516,184
- Report date
- 26 May 2026
- Price
- $40.05
- Ownership
- Direct
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 6,280,525
- Estimated value
- $251,516,184
- Report date
- 26 May 2026
- Price
- $40.05
- Ownership
- Direct
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 6,280,525
- Estimated value
- $251,516,184
- Report date
- 26 May 2026
- Price
- $40.05
- Ownership
- Direct
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 6,280,525
- Estimated value
- $251,516,184
- Report date
- 26 May 2026
- Price
- $40.05
- Ownership
- Direct
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 969,218
- Estimated value
- $30,326,831
- Report date
- 26 May 2026
- Price
- $31.29
- Ownership
- By Third Rock Ventures VI, L.P.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 969,218
- Estimated value
- $30,326,831
- Report date
- 26 May 2026
- Price
- $31.29
- Ownership
- By Third Rock Ventures VI, L.P.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 969,218
- Estimated value
- $30,326,831
- Report date
- 26 May 2026
- Price
- $31.29
- Ownership
- By Third Rock Ventures VI, L.P.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 969,218
- Estimated value
- $30,326,831
- Report date
- 26 May 2026
- Price
- $31.29
- Ownership
- By Third Rock Ventures VI, L.P.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 969,218
- Estimated value
- $30,326,831
- Report date
- 26 May 2026
- Price
- $31.29
- Ownership
- By Third Rock Ventures VI, L.P.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 969,218
- Estimated value
- $30,326,831
- Report date
- 26 May 2026
- Price
- $31.29
- Ownership
- By Third Rock Ventures VI, L.P.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 10 Jun 2024
- Price
- Ownership
- By Third Rock Ventures VI, L.P.
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 10 Jun 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 10 Jun 2024
- Price
- Ownership
- By Third Rock Ventures VI, L.P.
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Third Rock Ventures V, L.P. in Rapport Therapeutics, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.